Search

Search Results

1. Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) of prostate cancer: current and emerging applications

   Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) is transforming the management of patients with prostate cancer. In...

   Shamus Moran, Heather H. Cheng, ... Joseph E. Ippolito in Abdominal Radiology

   Article 22 February 2024
   

2. Prostate cancer screening—step** forward with MRI

   Abstract Objective

   To comprehensively review the literature on the integration of MRI as a diagnostic tool in prostate cancer screening and offer...

   Anwar R. Padhani, Ivo G. Schoots in European Radiology

   Article 08 May 2023

3. Updates on Management of Biochemical Recurrent Prostate Cancer

   Patients with biochemical recurrent prostate cancer (BCR) are a heterogeneous group, whereby a personalized approach to management is critical....

   Lauren Folgosa Cooley, Abhishek Srivastava, Neal D. Shore in Current Treatment Options in Oncology

   Article 03 January 2024

4. A nomogram based on biparametric magnetic resonance imaging for detection of clinically significant prostate cancer in biopsy-naïve patients

   Purpose

   This study aimed to develop and validate a model based on biparametric magnetic resonance imaging (bpMRI) for the detection of clinically...

   Beibei Hu, Huili Zhang, ... Yongming ** in Cancer Imaging

   Article Open access 04 September 2023
   

5. The potential role of the microbiota in prostate cancer pathogenesis and treatment

   The human body hosts a complex and dynamic population of trillions of microorganisms — the microbiota — which influences the body in homeostasis and...

   Nicolò Pernigoni, Christina Guo, ... Andrea Alimonti in Nature Reviews Urology

   Article 25 July 2023
   

6. Causal relationship between gut microbiota and prostate cancer contributes to the gut-prostate axis: insights from a Mendelian randomization study

   Background

   Changes in gut microbiota abundance have been linked to prostate cancer development. However, the causality of the gut-prostate axis...

   Li Wang, Yong-bo Zheng, ... **-yu Zhu in Discover Oncology

   Article Open access 03 March 2024
   

7. Prostate cancer biomarkers: from early diagnosis to precision treatment

   Prostate cancer (PCa) is the second most prevalent cancer in men. In 2020, approximately 1,414,259 new cases were reported that accounted for...

   Versha Dahiya, Sanjana Hans, ... Gargi Bagchi in Clinical and Translational Oncology

   Article 14 May 2024
   

8. Update on prostate cancer epidemiology in Morocco

   Background

   Prostate cancer stands as the most frequently diagnosed cancer among men globally, with over 600,000 new cases annually. In-depth...

   Chaimae Samtal, Laila Bouguenouch, ... Hicham Bekkari in African Journal of Urology

   Article Open access 27 April 2024
   

9. Simultaneous thulium laser resection of the prostate and transperineal prostate biopsy in clinically diagnosed metastatic prostate cancer with bladder outlet obstruction

   Metastatic prostate cancer (mPCa) patients complicated with bladder outlet obstruction (BOO) are often referred to a urologist. Androgen deprivation...

   Youwei Shi, Tianyu Cao, ... Yifeng **g in Lasers in Medical Science

   Article 18 August 2023

10. Key learning on the promise and limitations of MRI in prostate cancer screening

    Abstract

    MRI retains its ability to reduce the harm of prostate biopsies by decreasing biopsy rates and the detection of indolent cancers in...

    Anwar R. Padhani, Rebecka A. Godtman, Ivo G. Schoots in European Radiology

    Article 05 February 2024

11. Unlocking ferroptosis in prostate cancer — the road to novel therapies and imaging markers

    Ferroptosis is a distinct form of regulated cell death that is predominantly driven by the build-up of intracellular iron and lipid peroxides....

    Pham Hong Anh Cao, Abishai Dominic, ... Elavarasan Subramani in Nature Reviews Urology

    Article 16 April 2024
    

12. Cancer associated fibroblast secreted miR-432-5p targets CHAC1 to inhibit ferroptosis and promote acquired chemoresistance in prostate cancer

    Prostate cancer (PCa) ranks as the sixth most serious male malignant disease globally. While docetaxel (DTX) chemotherapy is the standard treatment...

    Jun Zhao, Jijie Shen, ... Sun Hongbin in Oncogene

    Article 20 May 2024
    

13. The role of multiparametric ultrasound in the detection of clinically significant prostate cancer

    Purpose

    Transrectal ultrasound (US) imaging is paramount to the successful completion of prostate biopsies. Certain US features have been associated...

    Nathan Jung, Renzo G. DiNatale, ... Christopher Porter in World Journal of Urology

    Article 06 August 2022
    

14. Total-body [⁶⁸ Ga]Ga-PSMA-11 PET/CT improves detection rate compared with conventional [⁶⁸ Ga]Ga-PSMA-11 PET/CT in patients with biochemical recurrent prostate cancer

    Purpose

    The purpose of this study was to assess whether total-body [ ⁶⁸ Ga]Ga-PSMA-11 PET/CT could improve the detection rate compared with...

    Yining Wang, Zijun Chen, ... Jianjun Liu in European Journal of Nuclear Medicine and Molecular Imaging

    Article 14 August 2023
    

15. Deep learning-based artificial intelligence for prostate cancer detection at biparametric MRI

    Purpose

    To present fully automated DL-based prostate cancer detection system for prostate MRI.

    Methods

    MRI scans from two institutions, were used for...

    Sherif Mehralivand, Dong Yang, ... Baris Turkbey in Abdominal Radiology

    Article 31 January 2022
    

16. Persistent organic pollutants promote aggressiveness in prostate cancer

    Increasing evidence points towards a causal link between exposure to persistent organic pollutants (POPs) with increased incidence and aggressivity...

    Julio Buñay, Myriam Kossai, ... Silvère Baron in Oncogene

    Article 17 August 2023
    

17. Biparametric MRI in prostate cancer during active surveillance: is it safe?

    Abstract

    Active surveillance (AS) is the preferred option for patients presenting with low-intermediate-risk prostate cancer. MRI now plays a crucial...

    Iztok Caglic, Nikita Sushentsev, ... Tristan Barrett in European Radiology

    Article Open access 24 April 2024
    

18. Evaluating the value of ¹⁸F-PSMA-1007 PET/CT in the detection and identification of prostate cancer using histopathology as the standard

    Background

    Prostate-specific membrane antigen (PSMA) PET/CT is a highly regarded radionuclide imaging modality for prostate cancer (PCa). This study...

    Liang Luo, Anqi Zheng, ... **aoyi Duan in Cancer Imaging

    Article Open access 03 November 2023
    

19. Diagnostic performance of regional systematic biopsy for prostate cancer stratified by PI-RADS and histologic zones

    Objectives

    To explore the diagnostic performance of targeted biopsy (TB) combined with regional systematic biopsy (RSB) in patients with different...

    Zhoujie Sun, Yi Liu, ... Cuijian Zhang in Insights into Imaging

    Article Open access 16 May 2024
    

20. Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of core number and location

    Purpose

    There is currently no consensus regarding the optimal number of multiparametric magnetic resonance imaging (MRI)-targeted biopsy (TB) cores...

    Robin Martin, Yassir Belahsen, ... Romain Diamand in World Journal of Urology

    Article 03 April 2023